key: cord-0310542-zr8mad03
authors: Usai, C.; Gibbons, J. M.; Pade, C.; Li, W.; McKnight, A.; Kennedy, P. T. F.; Gill, U. S.
title: The β-NGF/TrkA signalling pathway is associated with the production of anti- nucleoprotein IgG in convalescent COVID-19
date: 2021-11-11
journal: nan
DOI: 10.1101/2021.11.11.21266223
sha: b60836a3e7bba583b9b219cbeba530f08732b242
doc_id: 310542
cord_uid: zr8mad03

Background. The presentation of SARS-CoV-2 infection varies from asymptomatic to severe COVID. Similarly, high variability in the presence, titre and duration of specific antibodies has been reported. While some host factors determining these differences, such as age and ethnicity have been identified, the underlying molecular mechanisms underpinning these differences remain poorly defined. Methods. We analysed serum and PBMC from 17 subjects with a previous PCR confirmed SARS-CoV-2 infection and 10 unexposed volunteers following the first wave of the pandemic, in the UK. Anti-NP IgG and neutralising antibodies were measured, as well as a panel of infection and inflammation related cytokines. The virus-specific T cell response was determined by IFN-{gamma} ELISPOT and flow cytometry after over-night incubation of PBMCs with pools of selected SARS-CoV-2 specific peptides. Results. Seven of 17 convalescent subjects had undetectable levels of anti-NP IgG, and a positive correlation was shown between anti-NP IgG levels and the titre of neutralising antibodies (IC50). In contrast, a discrepancy was noted between antibody levels and T cell IFN-{gamma} production by ELISpot following stimulation with specific peptides. Among the analysed cytokines, {beta}-NGF and IL-1 levels were significantly different between anti-NP positive and negative subjects, and only {beta}-NGF significantly correlated with anti-NP positivity. Interestingly, CD4+ T cells of anti-NP negative subjects expressed lower amounts of the {beta}-NGF-specific receptor TrkA. Conclusions. Our results suggest that the {beta}-NGF/TrkA signalling pathway is associated with the production of anti-NP specific antibody in mild SARS-CoV-2 infection and the mechanistic regulation of this pathway in COVID-19 requires further investigation.

inflammation related cytokines. The virus-specific T cell response was determined by IFN-γ 23 ELISPOT and flow cytometry after over-night incubation of PBMCs with pools of selected SARS-

CoV-2 specific peptides.

Results. Seven of 17 convalescent subjects had undetectable levels of anti-NP IgG, and a positive 26 correlation was shown between anti-NP IgG levels and the titre of neutralising antibodies (IC50). In 27 contrast, a discrepancy was noted between antibody levels and T cell IFN-γ production by ELISpot 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 3 will allow better stratification according to the relative risk of developing severe disease, which may 63 be key to prioritise future treatment and vaccination strategies.

To address this question, we utilised a cohort of subjects sampled immediately following the first 65 wave of the COVID-19 pandemic in the UK; we analysed serum samples and peripheral 66 mononuclear cells (PBMC) from 7 anti-NP negative, 10 anti-NP positive COVID-19 convalescent 67 subjects, and 10 unexposed volunteers. We determined the titres of neutralising antibodies, the 68 presence of antigen-specific T cells, and serum levels of cytokines related to infection and 69 inflammation, to identify host factors associated with anti-NP IgG positivity. We identify an 70 association between the presence of circulating anti-NP antibodies and the nerve growth factor (β-71 NGF)/TrkA pathway, known to be active in lymphocytes and to be involved in inflammatory 72 conditions of the airways (22-25).

Forty donors were randomly selected from a previously published cohort (2) to create four sex-and CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 4 immediately frozen in fetal bovine serum 10% DMSO. Cells were thawed on the day of to the manufacturer's instructions and as previously described (2) . Anti-NPIgG leves in serum 98 samples were quantified using the Abbott Architect i2000 chemiluminescent microparticle 99 immunoassay (Architect) was for SARS-CoV-2 IgG (Abbott Diagnostics, IL, USA; Architect) 100 according to the manufacturer's instructions and as previously described (2).

SARS-CoV-2 microneutralisation assay was performed as described previously (14, 26) . VeroE6 103 cells were seeded in 96-well plates 24h prior to infection. Duplicate titrations of heat-inactivated 104 patient sera were incubated with 3x104 FFU SARS-CoV-2 virus (TCID100) at 37°C for 1h.

Serum/virus preparations were added to cells and incubated for 72h. Surviving cells were fixed in 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 5 124 SARS-CoV-2 peptide pools 125 Twenty peptides from the Spike, Membrane, Nucleoprotein and ORF-7a-2 proteins of SARS-CoV-2 126 containing T cell epitopes with known immunogenic properties (17,27) were purchased from 127 ProImmune Limited. The purity of the peptides was above 80%, and their composition was 128 confirmed by mass spectrometry analysis. Single peptides were reconstituted in DMSO and pooled 129 as outlined in Table 1 and used at a final concentration of 2 µM, reconstituted in RPMI.

IFN-γ ELISpot assays were performed with cryopreserved PBMCs, using human IFN-γ ELISPOT 132 Set (BD, 551849). PBMC were thawed, washed twice in RPMI media, and seeded at a final 133 concentration of 2 x 10 5 cells/100 µl and stimulated for 18 hours with 100 µl/well of each peptide pool 134 at a final concentration of 1µM/peptide/well, at 37°C, 5% CO 2 . Treatment with PMA (Abcam, 135 ab120297) and Ionomycin (Abcam ab120370) (final concentration 250 ng/ 5 µg/ ml respectively) 136 was used as a positive control, while RPMI was added to unstimulated cells. Spot forming units 137 (SFU) were quantified with a BIOREADER® 7000-F (BioSys GmbH). To quantify positive peptide-138 specific responses, 2× mean spots of the unstimulated wells were subtracted from the peptide-139 stimulated wells, and the results expressed as SFU/10 6 cells.

Frozen PBMCs were thawed and washed twice in 5 ml RPMI medium, centrifuged at 1500 rpm for 5 142 min and resuspended at a final concentration of 2 x 10 6 /ml in RPMI 10%FBS 2 µM Monensin 143 (eBioscience, 00-4505-51). 100 µl cell suspensions were stimulated in a 96-well plate for 18 hours 144 with 100 µl/well of each peptide pool, at a final concentration of 1µM/peptide/well, at 37°C, 5% CO 2 .

Treatment with PMA (Abcam, ab120297) and Ionomycin (Abcam ab120370) at the final 146 concentration of 50 ng/ml and 1 µg/ml respectively, was used as a positive control, while RPMI was 147 added to unstimulated cells. Cells were washed in 100 µl PBS 1x. Each well was incubated for 20 148 min at 4°C in the dark, with saturating concentrations (100 µl) of a mix of the following antibodies: 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint IFN-γ BV450 (BD Biosciences, clone B27), anti-TNF-α APC (BioLegend, clone Mab11), anti-IL-2 156 PE-CF594 (clone 5344.111, BD Horizon), anti-MIP-1β FITC (clone D21-12351 BD Pharmingen).

Cells were acquired on a BD-LSR II FACS Scan, and data were analysed using FlowJo (Tree Star 

We have previously determined the anti-NP IgM and IgG levels of 228 volunteers, after the first 168 wave of the pandemic in the United Kingdom (2) . Seven out of 87 participants who had had a 169 positive PCR test, had undetectable levels of anti-NP IgG, irrespective of symptomatology ( Table 2) .

Forty donors were randomly selected into four sex-and age-matched groups (Supplementary 183 Surprisingly, however those PCR positive anti-NP IgG negative subjects did not produce recordable 184 IFN-γ responses following stimulation with the pool of peptides derived from S ( Figure 1B) . Since

we considered the PCR status as one of the defining characteristics of our subject cohorts, we 186 elected to exclude the subjects where PCR results were not available from subsequent analyses.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 7 In addition to the Abbott Architect and Panbio assay for anti-NP IgG measurement, we determined 188 the presence and titre of neutralising antibodies (nAbs) which has the receptor binding domain 189 (RBD) of the S protein as their major target. In all subjects where anti-NP IgG positivity was 190 demonstrated, high nAb titres (IC50>200) were noted. Neutralising antibody titres were absent 191 (IC50<50), as expected, in all PCR negative subjects but also in two of seven PCR positive subjects 192 with negative anti-NP IgG status. In the five subjects where, anti-NP was negative but nAbs were 193 detectable, two displayed low titres (IC50=50-199) and three high titres (Figures 2A and 2B 

The peptide stimulation following incubation induced the expansion of a small percentage of 205 antigen-specific CD4+ T cells (<1% on average for IL-2, TNF-α and MIP-1β, and <5% for IFN-γ); the 206 frequency of IFN-y producing S-specific cells was higher in PCR positive anti-NP negative subjects 207 compared to unexposed volunteers, and no other significant difference was detected between 208 groups ( Figure 3A ). Among the studied cytokines from CD4+ T cells, TNF-α was produced by the 209 highest proportion of individuals across all groups, ranging from 25% to 100% of subjects depending 210 on the group and the peptide pool used for stimulation, while IL-2 was produced by the lowest 211 proportion of subjects (11%-50%) ( Figure 3C ).

Cytokine production from antigen-specific CD8+ T cells was similarly low when examining IL-2, MIP-213 1β and IFN-γ (<1% on average for IL-2 and MIP-1β, <5% for IFN-γ), but higher for TNF-α producing 214 cells (up to 4% on average). Moreover, only IL-2-producing S-specific CD8+ T cells were present at 215 a higher frequency in PCR positive anti-NP positive subjects than unexposed controls and no other 216 significant differences were detected ( Figure 3B ). MIP-1β was the cytokine produced by the highest 217 proportion of individuals across groups, ranging from 0% to 100%, depending on the group and the 218 peptide pool used for stimulation, followed by IL-2 and IFN-y (20% and 11% respectively, up to 219 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint 8 75%), while TNF-α from CD8+ T cells was produced by lower proportions of subjects (0% to 50%) 220 ( Figure 3D ).

However, when considering the cumulative response of cytokine production to the peptide pools, 222 differences between groups were identified. Within the PCR positive anti-NP positive group the 223 strongest cumulative cytokine production from CD4+ T cells was noted in response to the pool 224 derived from the S protein, with 12.5% of the subjects producing all analysed cytokines; all cytokines 225 were produced with the same frequency in response to this pool. This was followed, in decreasing 226 order, by the pools derived from M (TNF-α and IFN-γ being the predominant cytokines), NP (which 227 induced MIP-1β in 50% of cases), and ORF-7a-2 (mainly inducing TNF-α and MIP-1β). On the 228 contrary, within the PCR positive anti-NP negative group, the greatest cytokine production was 229 achieved in response to the pool derived from the M protein (25% of subjects producing all 230 cytokines, and all producing TNF-α). This was followed by the pools derived from NP (mainly 231 inducing TNF-α) and ORF-7a-2 (inducing the production of TNF-α, IFN-γ and MIP-1β with the same 232 frequencies). The peptide pool derived from S elicited the lowest cumulative cytokine production, 233 dominated by TNF-α and IFN-γ ( Figure 4A ).

A similar pattern was observed for CD8+ T cells from the PCR positive, anti-NP positive subjects, 235 with S inducing the strongest cumulative cytokine production (12.5% of subjects producing four 236 cytokines, all of them producing at least one cytokine, and MIP-1β being expressed with the highest 237 frequency). For the remaining pools, 25-37.5% of subjects failed to produce any cytokine; the 238 response was dominated by MIP-1β in the case of the pools derived from M and NP, and by MIP-1β 239 and IL-2 in the case of the peptide derived from ORF-7a-2. However, CD8+ T cells from 25% of the 240 PCR positive anti-NP negative subjects were also able to produce four cytokines in response to the 241 S pool. The lowest cytokine response was elicited by the peptide pool derived from NP, which 242 induced the production of only one or two cytokines per subject sample (TNF-α was induced in three 243 out of four subjects). The pools derived from M and ORF-7a-2 were able to elicit the production of 244 up to three cytokines in two and three subjects out of four respectively, but while the response to M 245 was dominated by MIP-1β, the cytokine induced at the highest frequency in response to ORF-7a-2 246 was IL-2 ( Figure 4B) . These results suggest that a differential hierarchy of response exists among 247 PCR positive subjects, according to their ability to produce anti-NP antibodies. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint and IL-12 p70 were found to positively correlate with anti-NP IgG levels ( Figure 5A and 5D, Table   253 3), and among them, β -NGF and IL-1α levels were significantly different between PCR positive, anti- 

Although the expression of TrkA on both CD4+ and CD8+ T cells appeared low, we were able to 267 demonstrate that by MFI of TrkA on CD4+ T cells positively correlated with serum levels of β -NGF in 268 the whole cohort ( Figure 6A ), yet this parallel was not seen for CD8+ T cells ( Figure 6B ). The 

We then compared TrkA expression (by MFI) on antigen specific CD4+ TrkA+ and CD8+ TrkA+ T 276 cells, to establish if there were discrepancies in relation to SARS-CoV-2 peptide specificities and this 277 signalling pathway. We did not detect any differences in cytokine producing cells between groups 278 with regards to antigen specific CD4+ TrkA+ cells, disparate to the findings on global CD4+ T cells 279 ( Figure 6G) . Overall, cytokine production from CD8+ T cells (by MFI) remained very low, and 280 although differences were detected between both peptide specificities and groups, we would 281 interpret these findings with caution ( Figure 6H ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10. 1101 /2021 Despite the success of the vaccine against SARS-CoV-2 in preventing severe COVID-19, there 

In this work, we analysed the SARS-CoV-2 specific T cell response and the cytokine profile of 17 295 mild COVID-19 convalescent subjects (positive PCR test) and 10 unexposed subjects (negative 296 PCR test, no symptoms) from a previously published cohort (2), to determine host factors 297 influencing primarily the production of anti-NP antibodies, but also neutralising antibodies. Our initial 298 observation was that seven out of eighty (8.75%) PCR confirmed subjects in our cohort had 299 undetectable anti-NP IgG, in line with other published cohorts where 1-10% of subject did not 300 seroconvert (4,10-12).

We analysed the T cell response by IFN-γ ELISPOT assay. Interesting we noted differences 302 between anti-NP IgG positive and anti-NP IgG negative convalescent patients, where none of the 303 anti-NP negative subjects were able to produce IFN-γ after stimulation with peptides derived from 304 the S protein. Of note, two out of the four analysed anti-NP IgG negative subjects had a detectable 305 IFN-γ response after overnight incubation with peptides derived from NP. This is not surprising, 306 since a SARS-CoV-2 specific T cell response has been detected in mild COVID-19 convalescent 307 subjects even in the absence of seroconversion (29), and the T cell response rather than humoral 308 response is considered to have a determining role in viral clearance (30) 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint cohort of healthcare workers, where a multi-specific T cell response was not always associated to 319 the presence of nAbs (14).

To further characterise the T cell response in our cohort we analysed the production of four effector 321 cytokines. While the frequencies of antigen-specific T cells were not different between groups, we 322 observed that T cells from anti-NP positive and negative subjects reacted differently to the peptide 323 pools in terms of number of cytokines produced after overnight stimulation. Particularly, CD4+T cells 324 from anti-NP positive subjects reacted preferentially to peptides derived from S (12.5% of them 325 produced four cytokines after stimulation), followed by the pools derived from M, NP and ORF-7a-2.

On the contrary, CD4+ T cells from anti-NP negative subjects reacted weakly to the S-derived pool 327 in comparison to the other antigens and reacted preferentially to M-derived peptides followed by the 328 pools derived from NP and ORF-7a-2. CD8+ T cells from anti-NP IgG positive subjects also strongly 329 reacted to the S-derived pool; CD8+ T cells from anti-NP negative subjects responded similarly to 330 the S pool, while reacted weakly to NP-derived peptides. These observations suggest that a 331 differential hierarchy of cytokine response exists among convalescent subjects, in relation to their 332 ability to produce anti-NP antibodies.

The presence of specific antibodies in our cohort does not directly correlate with the detection of the 334 corresponding antigen specific CD4+ T cells. While none of the four anti-NP subjects for whom 335 PBMC were available produced IFN-γ against S in the ELISPOT assay, three produced at least one 336 cytokine against the same pool when analysed by flow cytometry, and all had detectable nAbs. undetectable anti-NP IgG demonstrated neutralising activity. However, in our case, a direct 339 correlation between these results cannot be deduced since the S-derived peptides used in our 340 experiments do not cover the RBD. In addition, we were unable to study the T cell response of the 341 two anti-NP negative subjects lacking nAbs, since their PBMC were not available.

To further ascertain if soluble circulating factors may govern anti-NP production, we analysed a 343 panel of cytokines related to infection and inflammation from the serum of subjects between groups.

344 Surprisingly, we found that anti-NP positive and anti-NP negative subjects differed in the levels of 345 only two serum cytokines, β -NGF and IL-1α. A linear correlation was also found between Architect

Index values and serum levels of GM-CSF, β -NGF, IL-1α, PBEF and IL-12 p70. However, since the 347 relationship between Architect Index and the subject's IgG concentration is monotonic but not 348 necessarily linear across its range, we decided to consider the presence of anti-NP IgG as a binary 349 variable (either positive or negative), and perform a binary logistic regression, from which only β -

NGF levels positively correlated with anti-NP IgG positivity. On the contrary, no correlation was 351 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint found between β -NGF serum levels and nAbs titres, suggesting that the production of anti-NP and 352 nAbs may be subject to different dynamics and kinetics. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 13 production of anti-NP antibodies, which in turn reflects a different degree of inflammation caused by 385 SARS-CoV-2 infection.

We acknowledge the limitations of our study, in part linked to the difficulties in diagnosis during the 387 early phase of the pandemic, when PCR testing was not widely available. For this reason, we were 388 not able to determine the exact timeframe between symptom onset, PCR test and sample collection 389 for most of our subjects. Moreover, our sample size was limited, especially the group of PCR 

416 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint 419 would also like to thank all clinical and administrative staff at The Graham Hayton Unit, Royal 420 London Hospital for aiding with recruitment and clinical sample collection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 observation and decline of neutralizing antibody responses in the three months following 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 25.

Freund-Michel V, Frossard N. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint 

Treatment Coronavirus (COVID-19). StatPearls. StatPearls Publishing

SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London

Robust T 465 cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Discordant 468 neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection

Spike versus Nucleoprotein Antibody Responses Impact the Estimates of

Population-Based Seroprevalence Studies

Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease

Broad and strong memory CD4+

CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients

COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral 484 responses

T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Signatures Track with SARS-CoV-2 Survival. Immunity

Kinetics of SARS-CoV-2 specific IgM

IgG responses in COVID-19 patients. Emerg Microbes Infect

Expression of nerve growth factor and nerve 496 growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones

Nerve growth factor induces growth and differentiation of human

The authors would like to thank Dr Louisa James (Blizard Institute, Barts and The London SMD, 418 QMUL), Dr Sefina Arif and Norkhairin Yusuf (King's College London) for technical assistance. We

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101/2021.11.11.21266223 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted November 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021